Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see
how useful the combination of two drugs, panitumumab and trametinib, are in patients with
advanced colorectal cancer with KRAS, NRAS, or BRAF wild type (genes that are not mutated).
Panitumumab is a drug that is approved by Health Canada for the treatment of advanced
colorectal cancer with KRAS wild type. Panitumumab works by binding to and blocking the
protein, epidermal growth factor receptor (EGFR) from working.
Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a
mutation in the BRAF gene. Trametinib works by binding to and blocking mitogen-activated
protein kinase kinase (MEK) 1 and MEK2 from working.
Previous studies have shown that the combination of panitumumab and trametinib may be more
useful in KRAS, NRAS, or BRAF wild type colorectal cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society